Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Ford Motor Company (F) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Ford Motor Company — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Ford Motor Company trades at $14 (market cap $55.55B). The key difference: Ford Motor Company is far larger — about 6.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Ford Motor Company pays a 4.3% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | F | |
|---|---|---|
Market Cap | $8.04B | $55.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $17.44 |
52-Week Low | $241.71 | $10.82 |
Enterprise Value | $7.85B | $184.57B |
Dividend Yield | — | 4.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Ford (F) trades at $13.87, down 0.9% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with profitability metrics negative. Recent developments include a labor deal with Unifor, J.D. Power quality recognition, and plans for a $30,000 EV truck in 2027. Analyst consensus is mixed with 35% buy ratings and a $15.00 price target.
Ford faces execution risks in EV transition amid competitive pressures, though valuation appears reasonable with P/E of 11.84 and P/S of 0.29. The stock offers value potential if management can stabilize profitability, but investors should monitor EV execution and margin recovery given current negative ROE of -14.87% and ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
